Results 141 to 150 of about 23,640 (262)

Identification of key genes predicting the efficacy of mepolizumab in the treatment of severe eosinophilic asthma. [PDF]

Sci Rep
Xinmin P, Jinxia C, Fengyuan L.
europepmc   +1 more source

Eosinophil Counts and Asthma Severity in Children [PDF]

Journal of Allergy and Clinical Immunology, 2017
Cristine S. Rosario, Monica L. Cat, Herberto J. Chong Neto, Carlos A. Riedi, Nelson A. Rosario   +4 more
openaire   +1 more source

Efficacy of Full and Limited Endoscopic Sinus Surgery in Chronic Rhinosinusitis With Nasal Polyps: A Randomised Controlled Trial

Allergy, EarlyView.
Both Full and Limited FESS result in clinically meaningful relief of disease‐specific HRQoL and nasal breathing, effectively improving nasal symptoms and sleep disturbance in CRSwNP patients. Clinically meaningful difference in decrease of SNOT‐22 scores between the groups was not found at 12‐ and 24–month follow‐up.
P. Virkkula, S. Hammarén‐Malmi, A. Laulajainen‐Hongisto, M. Lilja, J. Wikstén, L. Hafrén, P. Kauppi, S. Reitsma, K. Pajala, J. Sahlman, S. Toppila‐Salmi   +10 more
wiley   +1 more source

Targeting Eosinophils in Asthmatic Inflammation: Benefits and Drawbacks

Journal of Inflammation Research
David Broide Department of Medicine, University of California San Diego, La Jolla, CA, 92093-0635, USACorrespondence: David Broide, Department of Medicine, University of California San Diego, La Jolla, CA, 92093-0635, USA, Email dbroide@health.ucsd ...
Broide D
doaj  

The Airway Transcriptome in Type 2 Cytokine Biomarker‐High and ‐Low Severe Asthma

Allergy, EarlyView.
This study distinguishes severe asthma–related airway transcriptomic changes from the effects of high‐dose ICS. Most dysregulated genes in severe asthma show concordance with corticosteroid responses. Corticosteroid‐resistant T2‐high asthma featured T2‐high and epithelial barrier gene upregulation, while T2‐low asthma featured Th1/IL‐17 signatures. ASM,
Jiashu Shen, Rekha Chaudhuri, Stephen Bicknell, Adel H. Mansur, Rahul Shrimanker, Ian D. Pavord, Stephen J. Fowler, Vanessa Brown, Lorcan P. McGarvey, Peter H. Howarth, Sven‐Erik Dahlén, Ian M. Adcock, Nazanin Zounemat‐Kermani, Joseph R. Arron, Liam G. Heaney, David F. Choy, Timothy S. C. Hinks, Emanuele Marchi, Peter Bradding, on behalf of the UK Medical Research Council Refractory Asthma Stratification programme (RASP‐UK)   +19 more
wiley   +1 more source

Functional respiratory imaging reveals early structural and functional airway responses to benralizumab in severe eosinophilic asthma. [PDF]

BMJ Open Respir Res
Conemans L, Deng Q, Simons SO, Franssen FME, Spruit MA, Hajian B.   +5 more
europepmc   +1 more source

Basophils in Immunity: Activation Pathways, Roles in Allergy and AllergoOncology and Application of the Basophil Activation Test

Allergy, EarlyView.
ABSTRACT Basophils, the least abundant leukocytes, are increasingly recognised as potent immunomodulators. Upon activation, they rapidly release preformed granule‐associated mediators including histamine and lipid mediators such as LTC4, while cytokine production occurs over a longer timescale, contributing to downstream immune responses.
Jitesh Chauhan, Sofia Vlasova, Alicia Chenoweth, Debra H. Josephs, Heather J. Bax, Sophia N. Karagiannis   +5 more
wiley   +1 more source

Persistent airway obstruction in severe eosinophilic asthma: targeting interleukin-5 and eosinophils. [PDF]

Eur Respir Rev
Hanania NA, Herth FJF.
europepmc   +1 more source

Serum‐Proteomic Profiling Reveals Distinct Atopic Dermatitis Severity‐Linked Signatures

Allergy, EarlyView.
This study aimed to identify a set of serum biomarkers that robustly distinguish prespecified severe from mild atopic dermatitis groups. Serum proteomic profiling distinguishes severe from mild atopic dermatitis, revealing an epithelial enriched severity footprint linked to LDH‐associated tissue injury and Th2/Th22 inflammation.
Jag S. Lally, Takeshi Yoshida, Shan Gao, Xueya Cai, Donald Y. M. Leung, Lisa A. Beck, Anna De Benedetto   +6 more
wiley   +1 more source

Clinical remission in patients with severe eosinophilic asthma treated with benralizumab over 24 months: Post hoc analysis of the ANANKE study. [PDF]

World Allergy Organ J
Canonica GW, Senna G, Brussino L, Aliani M, Altieri E, Bracciale P, Caiaffa MF, Cameli P, Caminati M, Caruso C, Centanni S, De Michele F, Del Giacco S, Di Marco F, Malerba L, Menzella F, Rogliani P, Romagnoli M, Schino P, Schroeder JW, Vultaggio A, D'Amato M, Pelaia G.   +22 more
europepmc   +1 more source